DDInter527 DDInter1960
Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997]
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt. To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.
Dextromethorphan {u} (Compound) resembles {v} (Compound) Levallorphan
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydromorphone
Dextromethorphan {u} (Compound) binds {v} (Gene) CYP3A4
Dextromethorphan {u} (Compound) upregulates {v} (Gene) PYCR1
Dextromethorphan {u} (Compound) palliates {v} (Disease) amyotrophic lateral sclerosis
Dextromethorphan {u} (Compound) is included by {v} (Pharmacologic Class) Uncompetitive NMDA Receptor Antagonists
Dextromethorphan {u} (Compound) downregulates {v} (Gene) GJA1
Dextromethorphan {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Dextromethorphan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Memantine
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rolapitant
Dextromethorphan (Compound) resembles Levallorphan (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone
Dextromethorphan (Compound) binds CYP3A4 (Gene)
Dextromethorphan (Compound) upregulates PYCR1 (Gene)
Dextromethorphan (Compound) palliates amyotrophic lateral sclerosis (Disease)
Dextromethorphan (Compound) is included by Uncompetitive NMDA Receptor Antagonists (Pharmacologic Class)
Dextromethorphan (Compound) downregulates GJA1 (Gene)
Dextromethorphan (Compound) causes Abdominal discomfort (Side Effect)
Dextromethorphan may cause a minor interaction that can limit clinical effects when taken with Memantine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant